Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer

Hyun Chang, S. E.Hyun Kim, Byoung Chul Cho, Sang Hyun Yoon, Hye Ryun Kim, Chang Geol Lee, Joo Hang Kim

    Research output: Contribution to journalArticle

    2 Scopus citations

    Abstract

    Background/Aim: We evaluated the anti-tumor activity and safety of cisplatin with irinotecan (IP) induction chemotherapy followed by chemoradiotherapy with etoposide/cisplatin (EP). Patients and Methods: Induction chemotherapy consisted of irinotecan i.v. and cisplatin i.v. and was administered on day 1 and day 8 of each cycle. Patients underwent two cycles of chemotherapy with a 3-week interval. In the absence of progressive disease, 66 Gy radiation was administered concurrently with etoposide on days 1 to 5 and 29 to 33, as well as with cisplatin on day 1, 8, 29, and 36. Results: Twenty patients were enrolled between July 2007 and December 2009. This study was closed prematurely due to lack of efficacy in induction chemotherapy. The overall response rate was 45% [95% confidence interval (CI), 25 to 65%], which did not meet the upper limit for first stage rejection of the treatment. The rates of 3-year progression-free survival and overall survival were 17.1% (95% CI, 0 to 36.8%) and 25% (95% CI, 0.2 to 49.8%), respectively. The primary toxicities included neutropenia, diarrhea and fatigue. Conclusion: This study failed to demonstrate a benefit for induction chemotherapy which was characterized by suboptimal antitumor activity and was poorly tolerated, with excess treatment-related toxicity.

    Original languageEnglish (US)
    Pages (from-to)3515-3521
    Number of pages7
    JournalAnticancer research
    Volume32
    Issue number8
    StatePublished - Aug 1 2012

      Fingerprint

    Keywords

    • Chemoradiotherapy
    • Cisplatin
    • Etoposide
    • Induction drug therapy
    • Irinotecan
    • Non-small cell lung neoplasms

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this

    Chang, H., Kim, S. E. H., Cho, B. C., Yoon, S. H., Kim, H. R., Lee, C. G., & Kim, J. H. (2012). Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer. Anticancer research, 32(8), 3515-3521.